Wire · operational-macro
Insight Molecular Diagnostics Inc. 8-K Filings
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 7 September 2026 · Fusion42 review
Insight Molecular Diagnostics Inc. disclosed receiving an Additional Information Request from the FDA regarding its GraftAssureDx kidney transplant rejection test submission, with a 180-day deadline for response and anticipation of further FDA meetings before Q4 2026. The company reported declining Q1 2026 revenues as it focused on FDA approval and highlighted progress with global transplant centers and commercial partnerships including Quest Diagnostics.
This Wire brief sits within Fusion42's coverage of Healthtech Infrastructure.
◆ ◆ The Wire takeaway
Your diagnostic startup must plan for longer FDA negotiation cycles on transplant tests as Insight's GraftAssureDx faces additional requests. Secure early partnerships like those Insight formed with Quest Diagnostics to maintain clinical trial and commercial momentum.
◆ Coverage
1 source · 7 Sep 2026
◆ Related on Wire
◆ Topics